EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma

Table 2 Correlation between the expression of EFNA3 and clinical characteristics in LUAD patients (n = 74)

Clinical Pathological	Number	EFNA3 expression		P value
Parameters		High(n = 38)	Low(n = 36)
Age				0.367
< 60	29	13	16
≥ 60	45	25	20
Sex				0.252
Male	48	27	21
Female	26	11	15
Tumor size				0.004*
T1	15	5	10
T2	43	19	24
T3 + T4	16	14	2
LN metastasis				0.035*
No	51	22	29
Yes	23	16	7
TNM stage				0.002*
I	31	10	21
II	35	20	15
III + IV	8	8	0

ISSN: 1475-2867